$BRTX Is Looking To Treat Chronic Pain Without The Need For Class-A Drugs
- 9 months ago
BioRestorative Therapies Inc. (NASDAQ: BRTX), a clinical-stage company specializing in stem cell-based therapies, hopes to provide better treatment options for the millions of Americans who do not want to take opioids, have struggled with addiction, or want better care.
BioRestorative’s leading product and novel drug BRTX-100 is an autologous stem cell product that uses the patient’s stem cells, which are harvested, cultured, and then injected directly into the patient’s body. BRTX-100 is a non-invasive treatment – the procedure is a single intra-discal injection that takes approximately 20 minutes. This product is currently being used in BioRestorative’s ongoing phase 2 clinical trial.
BioRestorative’s leading product and novel drug BRTX-100 is an autologous stem cell product that uses the patient’s stem cells, which are harvested, cultured, and then injected directly into the patient’s body. BRTX-100 is a non-invasive treatment – the procedure is a single intra-discal injection that takes approximately 20 minutes. This product is currently being used in BioRestorative’s ongoing phase 2 clinical trial.